Navigation Links
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
Date:5/17/2012

PARIS, May 17, 2012 /PRNewswire/ -- OrbusNeich today announced that two subgroup analyses from the REMEDEE trial assessing vascular healing of the company's Combo Dual Therapy Stent versus the TAXUS paclitaxel-eluting stent demonstrate an early advantage with the Combo Stent.  Presented at EuroPCR 2012, the data were obtained with frequency-domain optical coherence tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at nine-month follow-up.

An independent OCT core laboratory performed a blinded quantitative analysis of the percent strut coverage and in stent neointimal characteristics along with a qualitative assessment of neointimal tissue appearance and make-up of 23 Combo Stents and 10 TAXUS stents at nine-month follow-up.

Specifically, the data show that neointimal volumes and thicknesses as measured with OCT were comparable at nine months post-implantation for both the Combo Stent and TAXUS stent as determined by a blinded OCT core lab analysis. However, the qualitative analysis inside the stent showed a more homogenous neointimal tissue appearance in the Combo Stent compared to the TAXUS stent. In detail, the Combo Stent placements had statistically significant more homogeneous tissue appearance compared to the TAXUS stent placements (79.2% versus 40%).  Heterogeneous and layered tissue appearance was observed in 60% of the TAXUS stent placements and in 20.8% of the Combo Stent placements. Additionally, there were fewer microvessels and macrophage-like appearances inside the Combo Stent compared to the TAXUS stent: 8.3% versus 30% microvessels; 4.2% versus 10% macrophage-like appearances.

"These intriguing data possibly demonstrate a more homogenous tissue appearance with the Combo Stent versus a more heterogeneous appearance with the TAXUS stent in a blinded analysis," said Akiko Maehara, M.D.,director of Intravascular Imaging Core Laboratory at the Cardiovascular Research Foundation and assistant pro
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
3. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
10. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 A new Manhattan ... Decision Makers 2014, finds that members of ... care organizations (MCOs) and pharmacy benefits managers (PBMs) ... information.  A majority of formulary decision makers report ... during the formulary decision making process today than ...
(Date:7/14/2014)... July 14, 2014  Clinicians at a leading ... have become the first in the country to ... using an upgraded Clinac® medical linear accelerator from ... been enhanced with High Intensity Mode dose delivery ... Institute to shorten treatment times and deliver stereotactic ...
(Date:7/14/2014)... FAIRHOPE, Ala. , July 14, 2014  Patients ... of patients as Express Scripts and other major pharmacy ... coverage. The cuts will directly impact millions of patients ... of medical conditions, including persistent pain from cancer, diabetes ... will begin notifying some patients on July 15. ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... WASHINGTON, Nov. 20 Pharmaceutical,researchers are testing 92 ... related conditions, according to a report released today ... December,1 marks the 20th anniversary of "World AIDS ... the 1988 World Summit of Ministers of Health ...
... in Non-Small Cell Lung Cancer Expected to Inform ... for Experimental Cancer Treatment, MOUNTAIN VIEW, Calif., ... a leading provider of software,strategic consulting, and regulatory ... its Strategic Consulting Services Group,is using a quantitative ...
Cached Medicine Technology:92 Medicines and Vaccines now in Development for HIV/AIDS 292 Medicines and Vaccines now in Development for HIV/AIDS 3Pharsight Uses FDA Disease Model to Support Oncology Drug Development 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 3
(Date:7/14/2014)... Europe’s market for cardiac surgery devices ... by 2020, with the transcatheter heart valve devices sector ... transcatheter mitral valve repair (TMVR) segments) fuelling this growth. ... ?urrently the only THVI product on the market. However, ... and are anticipated to get CE approval by end-2020. ...
(Date:7/14/2014)... Since the announcement of the merger to form AAG HealthGAINS ... has been traveling to our network of facilities nationwide to ... our proprietary Maximum Sexual Performance Program for men and women. ... location on July 22nd, AAG Health NYC, 65 Broadway, Suite ... train our staff, and be on hand to answer patient ...
(Date:7/14/2014)... The North America Biostimulant Market report defines and ... and forecast of revenue. The biostimulants market in North ... in 2013 to $490.1 million by 2018, at a ... through the TOC of the North America Biostimulant Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/14/2014)... 14, 2014 Employers looking to ... employees with more benefit options must understand how ... online marketplaces, are the future of employee benefits. ... Jersey (Horizon BCBSNJ) is offering a free webinar, ... Offering More Options, to demonstrate how HorizonSelect, its ...
(Date:7/14/2014)... Continuing a steady trend of growth ... the heels of first-quarter success with Orange Regional Medical ... company founded by CEO and President Dr. Virginia Feldman ... three new members. Robert Poltenovage has joined ... John Steele, LPN and Angelica D’Amico have joined the ...
Breaking Medicine News(10 mins):Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 2Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 3Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2
... carcinoma in situDCISwho later develop invasive breast cancer in ... from breast cancer than those who do not develop ... 11 in the Journal of the National Cancer ... have compared breast conserving surgery (lumpectomy) to mastectomy and ...
... , FRIDAY, March 11 (HealthDay News) -- Taking ... but mostly in people at increased risk for the ... in their blood, according to a new study. ... or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced ...
... March 11 (HealthDay News) -- Watching your team win a ... be thrilling, but there may be a drawback: aggressive, testosterone-fueled ... found that traffic deaths at the game site and the ... game is over. Researchers at North Carolina State University ...
... are a burning issue. A straightforward guide to a closer understanding ... 2011). The Dose Makes the Poison: A Plain-Language Guide to Toxicology, ... leads to a distortion in many people,s conceptions of toxins and ... We are exposed to media reports on a daily basis of ...
... DETROIT Theories have long proposed that testosterone influences ... a recent study at Wayne State University give a ... mating behavior, and how testosterone is associated with dominance ... of an attractive woman. The study engaged ...
... causes AIDS invades human immune cells and causes ... can then infect new cells. A research team led ... Priv.-Doz. Dr. Barbara Mller of Heidelberg University Hospital have ... infected cell in virion release, and discovered that the ...
Cached Medicine News:Health News:DCIS patients who get invasive breast cancer have higher mortality 2Health News:Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People 2Health News:Fans of Winning Teams Linked to Fatal Crashes 2Health News:'The Dose Makes the Poison: A Plain-Language Guide to Toxicology,' 3rd Edition 2Health News:Wayne State study links testosterone with men's ability to 'woo' potential mates 2Health News:Pushing HIV out the door: How host factors aid in the release of HIV particles 2
LCD monitors....
This monitor is designed specifically for medical applications and is UL2601-1 listed....
Standard arthroscope with telescope (4 mm) for large joints....
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
Medicine Products: